You are here

Our science / Clinical Trials / Find a Trial / NCT03502616

Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)

Back to Search Print Save as PDF Bookmark Trial

NCT03502616

Last updated on November 9, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Arizona Arthritis & Rheumatology Associates, P.C.
Gilbert, Arizona, 85297 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Ankylosing Spondylitis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Has a diagnosis of Ankylosing Spondylitis (AS) based on the Modified New York Criteria
for AS (1984).

- Must have a radiograph of SI joints (AP Pelvis) documenting diagnosis of AS.

- Has active disease despite nonsteroidal anti-inflammatory drug (NSAID) therapy or
intolerant to NSAIDs.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- History of known or suspected complete ankylosis of the spine.

- History of allergies, intolerance or hypersensitivity to lactose or tofacitinib.

- History of any other rheumatic disease.

- Any subject with condition affecting oral drug absorption.

NCT03502616
Pfizer
Recruiting
Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Ankylosing Spondylitis
Extension Study Evaluating Etanercept in Ankylosing Spondylitis
NCT00410046
All Genders
18+
Years
Multiple Sites
Ankylosing Spondylitis
Effects of Etanercept on the Heart, Veins and Thickness of Certain Major Arteries In Ankylosing Spondylitis Patients
NCT00910273
All Genders
18+
Years
Multiple Sites
Ankylosing Spondylitis
Study Of Celecoxib Or Diclofenac For Efficacy and Safety In Chinese Patients With Ankylosing Spondylitis
NCT00762463
All Genders
18+
Years
Multiple Sites
Ankylosing Spondylitis
Observational Non-Interventional Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis
NCT01188655
All Genders
Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)
A Phase 3, Randomized, Double Blind, Placebo Controlled, Study Of The Efficacy And Safety Of Tofacitinib In Subjects With Active Ankylosing Spondylitis (as)
The purpose of this study is to determine if tofacitinib is safe and effective in subjects with active ankylosing spondylitis.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Ankylosing Spondylitis
Drug: Tofacitinib
Oral administration twice per day
  • Experimental: Tofacitinib
    Intervention: Drug: Tofacitinib
  • Placebo Comparator: Placebo
    Intervention: Drug: Tofacitinib
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
240
Same as current
August 2, 2020
August 2, 2020   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Has a diagnosis of Ankylosing Spondylitis (AS) based on the Modified New York Criteria for AS (1984).
  • Must have a radiograph of SI joints (AP Pelvis) documenting diagnosis of AS.
  • Has active disease despite nonsteroidal anti-inflammatory drug (NSAID) therapy or intolerant to NSAIDs.

Exclusion Criteria:

  • History of known or suspected complete ankylosis of the spine.
  • Subject who has previously participated in any study of tofacitinib.
  • History of any other rheumatic disease.
  • Any subject with condition affecting oral drug absorption.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No

Contact: Pfizer CT.gov Call Center 1-800-718-1021 [email protected]
Not Provided
 
 
NCT03502616
A3921120
AS ( Other Identifier: Alias Study Number )
Yes
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: Yes
Plan Description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/da...
URL: http://
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
April 2018

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now